US6706712B2 - Cyclic derivatives as modulators of chemokine receptor activity - Google Patents

Cyclic derivatives as modulators of chemokine receptor activity Download PDF

Info

Publication number
US6706712B2
US6706712B2 US10/027,644 US2764401A US6706712B2 US 6706712 B2 US6706712 B2 US 6706712B2 US 2764401 A US2764401 A US 2764401A US 6706712 B2 US6706712 B2 US 6706712B2
Authority
US
United States
Prior art keywords
substituted
amino
crr
alkyl
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US10/027,644
Other languages
English (en)
Other versions
US20030004151A1 (en
Inventor
Robert Cherney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Priority to US10/027,644 priority Critical patent/US6706712B2/en
Assigned to BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) reassignment BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHERNEY, ROBERT
Publication of US20030004151A1 publication Critical patent/US20030004151A1/en
Priority to US10/706,448 priority patent/US7045521B2/en
Application granted granted Critical
Publication of US6706712B2 publication Critical patent/US6706712B2/en
Assigned to BRISTOL-MYERS SQUIBB PHARMA COMPANY reassignment BRISTOL-MYERS SQUIBB PHARMA COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHERNEY, ROBERT
Priority to US11/315,385 priority patent/US7572813B2/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • This invention relates generally to modulators of chemokine receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory diseases, allergic and autoimmune diseases, and in particular, asthma, rheumatoid arthritis, atherosclerosis, and multiple sclerosis.
  • Chemokines are chemotactic cytokines, of molecular weight 6-15 kDa, that are released by a wide variety of cells to attract and activate, among other cell types, macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils (reviewed in: Luster, New Eng. J. Med . 1998, 338, 436-445 and Rollins, Blood 1997, 90, 909-928).
  • CXC chemotactic cytokines
  • CC chemotactic cytokines, of molecular weight 6-15 kDa, that are released by a wide variety of cells to attract and activate, among other cell types, macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils (reviewed in: Luster, New Eng. J. Med . 1998, 338, 436-445 and Rollins, Blood 1997, 90, 909-928).
  • CXC single amino acid
  • CC adjacent
  • the CXC chemokines such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils and T lymphocytes, whereas the CC chemokines, such as RANTES, MIP-1 ⁇ , MIP-1 ⁇ , the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5) and the eotaxins ( ⁇ 1 and ⁇ 2) are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, dendritic cells, and basophils.
  • IL-8 interleukin-8
  • NAP-2 neutrophil-activating protein-2
  • MGSA melanoma growth stimulatory activity protein
  • lymphotactin-1 lymphotactin-1
  • lymphotactin-2 both C chemokines
  • fractalkine a CXXXC chemokine
  • chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in: Horuk, Trends Pharm. Sci . 1994, 15, 159-165) which are termed “chemokine receptors.” On binding their cognate ligands, chemokine receptors transduce an intracellular signal though the associated trimeric G proteins, resulting in, among other responses, a rapid increase in intracellular calcium concentration, changes in cell shape, increased expression of cellular adhesion molecules, degranulation, and promotion of cell migration.
  • CCR-1 or “CKR-1” or “CC-CKR-1” [MIP-1 ⁇ , MCP-3, MCP-4, RANTES] (Ben-Barruch, et al., Cell 1993, 72, 415-425, and Luster, New Eng. J. Med . 1998, 338, 436-445); CCR-2A and CCR-2B (or “CKR-2A”/“CKR-2B” or “CC-CKR-2A”/“CC-CKR-2B”) [MCP-1, MCP-2, MCP-3, MCP-4, MCP-5] (Charo, et al., Proc. Natl.
  • CCR-3 [eotaxin-1, eotaxin-2, RANTES, MCP-3, MCP-4] [Combadiere, et al., J. Biol. Chem . 1995, 270, 16491-16494, and Luster, New Eng. J. Med . 1998, 338, 436-445); CCR-4 (or “CKR-4” or “CC-CKR-4”) [TARC, MIP-1 ⁇ , RANTES, MCP-1] (Power, et al., J. Biol. Chem .
  • CCR-5 or “CKR-5” OR “CC-CKR-5” [MIP-1 ⁇ , RANTES, MIP-1 ⁇ ] (Sanson, et al., Biochemistry 1996, 35, 3362-3367); CCR-6 (or “CKR-6” or “CC-CKR-6”) [LARC] (Baba, et al., J. Biol. Chem . 1997, 272, 14893-14898); CCR-7 (or “CKR-7” or “CC-CKR-7”) [ELC] (Yoshie et al., J. Leukoc. Biol .
  • CCR-8 or “CKR-8” or “CC-CKR-8” [I-309, TARC, MIP-1 ⁇ ] (Napolitano et al., J. Immunol ., 1996, 157, 2759-2763, and Bernardini, et al., Eur. J. Immunol . 1998, 28, 582-588); CCR-10 (or “CKR-10” or “CC-CKR-10”) [MCP-1, MCP-3] (Bonini, et al., DNA and Cell Biol . 1997, 16, 1249-1256); and CCR-11 [MCP-1, MCP-2, and MCP-4] (Schweickert, et al., J. Biol. Chem . 2000, 275, 90550).
  • mammalian chemokine receptors In addition to the mammalian chemokine receptors, mammalian cytomegaloviruses, herpesviruses and poxviruses have been shown to express, in infected cells, proteins with the binding properties of chemokine receptors (reviewed in: Wells and Schwartz, Curr. Opin. Biotech . 1997, 8, 741-748).
  • Human CC chemokines such as RANTES and MCP-3, can cause rapid mobilization of calcium via these virally encoded receptors. Receptor expression may be permissive for infection by allowing for the subversion of normal immune system surveillance and response to infection.
  • human chemokine receptors such as CXCR4, CCR2, CCR3, CCR5 and CCR8, can act as co-receptors for the infection of mammalian cells by microbes as with, for example, the human immunodeficiency viruses (HIV).
  • HAV human immunodeficiency viruses
  • chemokines and their cognate receptors have been implicated as being important mediators of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis (reviewed in: Bharat K. Trivedi, et al, Ann. Reports Med. Chem . 2000, 35, 191; John Saunders and Christine M. Tarby, Drug Disc. Today 1999, 4, 80; Brett A. Premack and Thomas J. Schall, Nature Medicine 1996, 2, 1174).
  • the chemokine monocyte chemoattractant-1 (MCP-1) and its receptor CC Chemokine Receptor 2 (CCR-2) play a pivotal role in attracting leukocytes to sites of inflammation and in subsequently activating these cells.
  • MCP-1 monocyte chemoattractant-1
  • CCR-2 Chemokine Receptor 2
  • MCP-1 binds to CCR-2, it induces a rapid increase in intracellular calcium concentration, increased expression of cellular adhesion molecules, cellular degranulation, and the promotion of leukocyte migration. Demonstration of the importance of the MCP-1/CCR-2 interaction has been provided by experiments with genetically modified mice.
  • MCP-1 ⁇ / ⁇ mice had normal numbers of leukocytes and macrophages, but were unable to recruit monocytes into sites of inflammation after several different types of immune challenge (Bao Lu, et al., J. Exp. Med . 1998, 187, 601). Likewise, CCR-2 ⁇ / ⁇ mice were unable to recruit monocytes or produce interferon- ⁇ when challenged with various exogenous agents; moreover, the leukocytes of CCR-2 null mice did not migrate in response to MCP-1 (Landin Boring, et al., J. Clin. Invest . 1997, 100, 2552), thereby demonstrating the specificity of the MCP-1/CCR-2 interaction.
  • MCP-1(9-76) MCP-1(9-76) was shown both to prevent disease onset and to reduce disease symptoms (depending on the time of administration) in the MRL-lpr mouse model of arthritis (Jiang-Hong Gong, et al., J. Exp. Med . 1997, 186, 131).
  • MCP-1 is overexpressed in various disease states not mentioned above. These reports provide strong correlative evidence that MCP-1 antagonists could be useful therapeutics for such diseases.
  • Two reports describe the overexpression of MCP-1 rats with induced brain trauma (J. S. King, et al., J. Neuroimmunol . 1994, 56, 127, and Joan W.
  • MCP-1 is overexpressed in the brains and cerebrospinal fluid of patients with HIV-1-associated dementia.
  • CCR-2 has been implicated as a co-receptor for some strains of HIV (B. J. Doranz, et al., Cell 1996, 85, 1149). It has also been determined that the use of CCR-2 as an HIV co-receptor can be correlated with disease progression (Ruth I. Connor, et al., J. Exp. Med . 1997, 185, 621). This finding is consistent with the recent finding that the presence of a CCR-2 mutant, CCR2-64I, is positively correlated with delayed onset of HIV in the human population (Michael W. Smith, et al., Science 1997, 277, 959). Although MCP-1 has not been implicated in these processes, it may be that MCP-1 antagonists that act via binding to CCR-2 may have beneficial therapeutic effects in delaying the disease progression to AIDS in HIV-infected patients.
  • CCR-2 is also the receptor for the chemokines MCP-2, MCP-3, MCP-4, and MCP-5 (Luster, New Eng. J. Med . 1998, 338, 436-445). Since it is presumed that the new compounds of formula (I) described herein antagonize MCP-1 by binding to the CCR-2 receptor, it may be that these compounds of formula (I) are also effective antagonists of the actions of MCP-2, MCP-3, MCP-4, and MCP-5 that are mediated by CCR-2. Accordingly, when reference is made herein to “antagonism of MCP-1,” it is to be assumed that this is equivalent to “antagonism of chemokine stimulation of CCR-2.”
  • the present invention provides novel antagonists or partial agonists/antagonists of MCP-1 receptor activity, or pharmaceutically acceptable salts or prodrugs thereof.
  • the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
  • the present invention provides a method for treating rheumatoid arthritis, multiple sclerosis, and atherosclerosis, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
  • the present invention provides a method for treating inflammatory diseases, comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
  • the present invention provides novel cyclic derivatives for use in therapy.
  • the present invention provides the use of novel cyclic derivatives for the manufacture of a medicament for the treatment of inflammatory diseases.
  • ring B is a cycloalkyl group of 3 to 8 carbon atoms wherein the cycloalkyl group is saturated or partially unsaturated; or a heterocycle of 3 to 7 atoms wherein the heterocycle is saturated or partially unsaturated, the heterocycle containing a heteroatom selected from —O—, —S—, —S( ⁇ O)—, —S( ⁇ O) 2 —, and —N(R 4 )—, the heterocycle optionally containing a —C(O)—; ring B being substituted with 0-2 R 5 ;
  • Z is selected from a bond, —C(O)—, —C(O)NH—, —C(S)NH—, —SO 2 —, and —SO 2 NH—;
  • R 1a and R 1b are independently selected from H, C 1-4 alkyl, C 1-4 cycloalkyl, CF 3 , or alternatively, R 1a and R 1b are taken together to from ⁇ O;
  • R 1 is selected from a C 6-10 aryl group substituted with 0-5 R 6 and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 6 ;
  • R 2 is selected from a C 6-10 aryl group substituted with 0-5 R 7 and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 7 ;
  • R 4 is selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, (CRR) q OH, (CRR) t SH, (CRR) t OR 4d , (CHR) t SR 4d , (CRR) t NR 4a R 4a , (CRR) q C(O)OH, (CRR) r C(O)R 4b , (CRR) r C(O)NR 4a R 4a , (CRR) t OC(O)NR 4a R 4a , (CRR) t NR 4a C(O)OR 4d , (CRR) t NR 4a C(O)R 4b , (CRR) r C(O)OR 4b , (CRR) t OC(O)R 4b , (CRR) r S(O) p R 4b , (CRR) r S(O) 2 NR 4a R 4a
  • R 4a is independently selected from H, methyl substituted with 0-1 R 4c , C 2-6 alkyl substituted with 0-3 R 4e , C 3-8 alkenyl substituted with 0-3 R 4e , C 3-8 alkynyl substituted with 0-3 R 4e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-4 R 4e , and a (CHR) r -4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 4e ;
  • R 4b is selected from H, C 1-6 alkyl substituted with 0-3 R 4e , C 3-8 alkenyl substituted with 0-3 R 4e , C 3-8 alkynyl substituted with 0-3 R 4e , a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 4e , and a (CHR) r -4-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 4e ;
  • R 4 c is independently selected from —C(O)R 4b , —C(O)OR 4d , —C(O)NR 4f R 4f , and (CH 2 ) r phenyl;
  • R 4d is selected from methyl, CF 3 , C 1-6 alkyl substituted with 0-3 R 4e , C 3-8 alkenyl substituted with 0-3 R 4e , C 3-8 alkynyl substituted with 0-3 R 4e , and a C 3-10 carbocyclic residue substituted with 0-3 R 4e ;
  • R 4e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 4f R 4f , —C(O)R 4i , —C(O)OR 4j , —C(O)NR 4h R 4h , —OC(O)NR 4h R 4h , —NR 4h C(O)NR 4h R 4h , —NR 4h C(O)OR 4j , and (CH 2 ) r phenyl;
  • R 4f at each occurrence, is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, and phenyl;
  • R 4h is independently selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, and a (CH 2 ) r —C 3-10 carbocyclic;
  • R 4i at each occurrence, is selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, and a (CH 2 ) r —C 3-6 carbocyclic residue;
  • R 4j at each occurrence, is selected from CF 3 , C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, and a C 3-10 carbocyclic residue;
  • R 5 is independently selected from H, C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r OH, (CRR) r SH, (CRR) r OR 5d , (CRR) r SR 5d , (CRR) r NR 5a R 5a , (CRR) r C(O)OH, (CRR) r C(O)R 5b , (CRR) r C(O)NR 5a R 5a , (CRR) r NR 5a C(O)R 5b , (CRR) r OC(O)NR 5a R 5a , (CRR) r NR 5a C(O)OR 5d , (CRR) r NR 5a C(O)NR 5a R 5a , (CRR) r NR 5a C(O)H, (CRR) r C(O)OR 5b , (CRR) r
  • R 5a is independently selected from H, methyl substituted with 0-1 R 5g , C 2-6 alkyl substituted with 0-2 R 5e , C 3-8 alkenyl substituted with 0-2 R 5e , C 3-8 alkynyl substituted with 0-2 R 5e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-5 R 5e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 5e ;
  • R 5b is selected from C 1-6 alkyl substituted with 0-3 R 5e , C 3-8 alkenyl substituted with 0-2 R 5e , C 3-8 alkynyl substituted with 0-2 R 5e , a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 5e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 5e ;
  • R 5c is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , NO 2 , CN, (CH 2 ) r NR 5f R 5f , (CH 2 ) r OH, (CH 2 ) r OC 1-4 alkyl, (CH 2 ) r SC 1-4 alkyl, (CH 2 ) r C(O)OH, (CH 2 ) r C(O)R 5b , (CH 2 ) r C(O)NR 5f R 5f , (CH 2 ) r NR 5f C(O)R 5b , (CH 2 ) r C(O)OC 1-4 alkyl, (CH 2 ) r OC(O)R 5b , (CH 2 ) r C( ⁇ NR 5f )NR
  • R 5d is selected from methyl, CF 3 , C 2-6 alkyl substituted with 0-2 R 5e , C 3-8 alkenyl substituted with 0-2 R 5e , C 3-8 alkynyl substituted with 0-2 R 5e , and a C 3-10 carbocyclic residue substituted with 0-3 R 5e ;
  • R 5e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 ,(CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 5f R 5f , and (CH 2 ) r phenyl;
  • R 5f at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
  • R 5g is independently selected from —C(O)R 5b , —C(O)OR 5d , —C(O)NR 5f R 5f , and (CH 2 ) r phenyl;
  • R at each occurrence, is selected from H, C 1-6 alkyl substituted with R 5e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 5e ;
  • R 6 is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 6a R 6a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 6d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 6d , (CR′R′) r SC(O)(CR′R′) r R 6b , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 6b , (CR′R′) r NR 6a R 6a , (CR′R′) r C(
  • R 6 on adjacent atoms on R 1 may join to form a cyclic acetal
  • R 6a is selected from H, methyl substituted with 0-1 R 6g , C 2-6 alkyl substituted with 0-2 R 6e , C 3-8 alkenyl substituted with 0-2 R 6e , C 3-8 alkynyl substituted with 0-2 R 6e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-5 R 6e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 6e ;
  • R 6b is selected from H, C 1-6 alkyl substituted with 0-2 R 6e , C 3-8 alkenyl substituted with 0-2 R 6e , C 3-8 alkynyl substituted with 0-2 R 6e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0-3 R 6e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 6e ;
  • R 6d is selected from C 3-8 alkenyl substituted with 0-2 R 6e , C 3-8 alkynyl substituted with 0-2 R 6e , methyl, CF 3 , C 2-6 alkyl substituted with 0-3 R 6e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-3 R 6e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 6e ;
  • R 6e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl;
  • R 6f at each occurrence, is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
  • R 6g is independently selected from —C(O)R 6b , —C(O)OR 6d , —C(O)NR 6f R 6f , and (CH 2 ) r phenyl;
  • R 7 is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 7a R 7a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 7d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r (CR′R′) r R 7d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 7b , (CR′R′) r C(O)NR 7a R 7a , (CR′R′) r NR 7f C(O)(CR′R′) r R 7b , (CR′R′) r C(
  • R 7 on adjacent atoms on R 2 may join to form a cyclic acetal
  • R 7a is independently selected from H, methyl substituted with 0-1 R 7g , C 2-6 alkyl substituted with 0-2 R 7e , C 3-8 alkenyl substituted with 0-2 R 7e , C 3-8 alkynyl substituted with 0-2 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-5 R 7e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 7e ;
  • R 7b is selected from C 1-6 alkyl substituted with 0-2 R 7e , C 3-8 alkenyl substituted with 0-2 R 7e , C 3-8 alkynyl substituted with 0-2 R 7e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0-3 R 7e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 7e ;
  • R 7d is selected from C 3-8 alkenyl substituted with 0-2 R 7e , C 3-8 alkynyl substituted with 0-2 R 7e , methyl, CF 3 , C 2-6 alkyl substituted with 0-3 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-3 R 7e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 7e ;
  • R 7e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
  • R 7f is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
  • R 7g is independently selected from —C(O)R 7b , —C(O)OR 7d , —C(O)NR 7f R 7f , and (CH 2 ) r phenyl;
  • R′ at each occurrence, is selected from H, C 1-6 alkyl substituted with R 6e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e ;
  • R 8 is selected from H, C 1-4 alkyl, and C 3-4 cycloalkyl
  • R 9 is selected from H, C 1-4 alkyl, C 3-4 cycloalkyl, and (CH 2 )—R 1 ;
  • R 10 and R 10a are independently selected from H, and C 1-4 alkyl substituted with 0-1 R 10b ,
  • R 10 and R 10a can join to form a C 3-6 cycloalkyl
  • R 10b is independently selected from —OH, —SH, —NR 10c R 10c , —C(O)NR 10c R 10c , and —NHC(O)R 10c ;
  • R 10c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl
  • R 11 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 11d , (CHR) q S(O) p R 11d , (CHR) r C(O)R 11b , (CHR) r NR 11a R 11a , (CHR) r C(O)NR 11a R 11a , (CHR) r C(O)NR 11a OR 11d , (CHR) q NR 11a C(O)R 11b , (CHR) q NR 11a C(O)OR 11d , (CHR) q OC(O)NR 11a R 11a , (CHR) r C(O)OR 11d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0-5 R 11e , and a (CHR) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from
  • R 11a is independently selected from H, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-5 R 11e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 11e ;
  • R 11b is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 11e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 11e ;
  • R 11d is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0-3 R 11e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 11e ;
  • R 11e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 11f R 11f , and (CH 2 ) r phenyl;
  • R 11f at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
  • R 12 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 12d , (CHR) q S(O) p R 12d , (CHR) r C(O)R 12b , (CHR) r NR 12a R 12a , (CHR) r C(O)NR 12a R 12a , (CHR) r C(O)NR 12a OR 12d , (CHR) q NR 12a C(O)R 12b , (CHR) q NR 12a C(O)COR 12d , (CHR) q OC(O)NR 12a R 12a , (CHR) r C(O)OR 12d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0-5 R 12e , and a (CHR) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected
  • R 12a is independently selected from H, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-5 R 12e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 12e ;
  • R 12b is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 12e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 12e ;
  • R 12d is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0-3 R 12e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 12e ;
  • R 12e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 12f R 12f , and (CH 2 ) r phenyl;
  • R 12f at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
  • R 13 at each occurrence, is independently selected from methyl, C 2-4 alkyl substituted with 0-1 R 13b ;
  • R 13b is selected from —OH, —SH, —NR 13c R 13c , —C(O)NR 13c R 13c , and —NHC(O)R 13c ;
  • R 13c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl
  • n is selected from 1 and 2;
  • n is selected from 0 and 1;
  • p at each occurrence, is independently selected from 0, 1, and 2;
  • q at each occurrence, is independently selected from 1, 2, 3, and 4;
  • r at each occurrence, is independently selected from 0, 1, 2, 3, and 4;
  • s at each occurrence, is independently selected from 0 and 1;
  • t at each occurrence, is independently selected from 2, 3, and 4.
  • ring B is a cycloalkyl group of 3 to 8 carbon atoms wherein the cycloalkyl group is saturated or partially unsaturated; or a heterocycle of 3 to 7 atoms wherein the heterocycle is saturated or partially unsaturated, the heterocycle containing a heteroatom selected from —O—, —S—, —S( ⁇ O)—, —S( ⁇ O) 2 —, and —N(R 4 )—, the heterocycle optionally containing a —C(O)—; ring B being substituted with 0-2 R 5 ;
  • Z is selected from a bond, —C(O)—, —C(O)NH—, —C(S)NH—, —SO 2 —, and —SO 2 NH—;
  • R 1a and R 1b are independently selected from H, C 1-4 alkyl, C 1-4 cycloalkyl, CF 3 , or alternatively, R 1a and R 1b are taken together to from ⁇ O;
  • R 1 is selected from a C 6-10 aryl group substituted with 0-5 R 6 and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 6 ;
  • R 2 is selected from a C 6-10 aryl group substituted with 0-5 R 7 and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 7 ;
  • R 4 is selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, (CRR) q OH, (CRR) t SH, (CRR) t OR 4d , (CHR) t SR 4d , (CRR) t NR 4a R 4a , (CRR) q C(O)OH, (CRR) r C(O)R 4b , (CRR) r C(O)NR 4a R 4a , (CRR) t OC(O)NR 4a R 4a , (CRR) t NR 4a C(C)OR 4d , (CRR) t NR 4a C(O)R 4b , (CRR) r C(O)OR 4b , (CRR) t OC(O)R 4b , (CRR) r S(O) p R 4b , (CRR) r S(O) 2 NR 4a R 4a
  • R 4a is independently selected from H, methyl substituted with 0-1 R 4c , C 2-6 alkyl substituted with 0-3 R 4e , C 3-8 alkenyl substituted with 0-3 R 4e , C 3-8 alkynyl substituted with 0-3 R 4e , and a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-4 R 4e ;
  • R 4b at each occurrence, is selected from H, C 1-6 alkyl substituted with 0-3 R 4e , C 3-8 alkenyl substituted with 0-3 R 4e , C 3-8 alkynyl substituted with 0-3 R 4e , and a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 4e ;
  • R 4 c is independently selected from —C(O)R 4b , —C(O)OR 4d , —C(O)NR 4f R 4f , and (CH 2 ) r phenyl;
  • R 4d is selected from methyl, CF 3 , C 1-6 alkyl substituted with 0-3 R 4e , C 3-8 alkenyl substituted with 0-3 R 4e , C 3-8 alkynyl substituted with 0-3 R 4e , and a C 3-10 carbocyclic residue substituted with 0-3 R 4e ;
  • R 4e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 4f R 4f , —C(O)R 4i , —C(O)OR 4i , —C(O)NR 4h R 4h , —OC(O)NR 4h R 4h , —NR 4h C(O)NR 4h R 4h , —NR 4h C(O) OR 4j , and (CH 2 ) r phenyl;
  • R 4f at each occurrence, is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, and phenyl;
  • R 4h is independently selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, and a (CH 2 ) r —C 3-10 carbocyclic;
  • R 4i at each occurrence, is selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, and a (CH 2 ) r —C 3-6 carbocyclic residue;
  • R 4j at each occurrence, is selected from CF 3 , C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, and a C 3-10 carbocyclic residue;
  • R 5 is independently selected from H, C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r OH, (CRR) r SH, (CRR) r OR 5d , (CRR) r SR 5d , (CRR) r NR 5a R 5a , (CRR) r C(O)OH, (CRR) r C(O)R 5b , (CRR) r C(O)NR 5a R 5a , (CRR) r NR 5a C(O)R 5b , (CRR) r OC(O)NR 5a R 5a , (CRR) r NR 5a C(O)OR 5d , (CRR) r NR 5a C(O)NR 5a R 5a , (CRR) r NR 5a C(O)H, (CRR) r C(O)OR 5b , (CRR) r
  • R 5a is independently selected from H, methyl substituted with 0-1 R 5g , C 2-6 alkyl substituted with 0-2 R 5e , C 3-8 alkenyl substituted with 0-2 R 5e , C 3-8 alkynyl substituted with 0-2 R 5e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-5 R 5e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 5e ;
  • R 5b is selected from C 1-6 alkyl substituted with 0-3 R 5e , C 3-8 alkenyl substituted with 0-2 R 5e , C 3-8 alkynyl substituted with 0-2 R 5e , a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 5e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 5e ;
  • R 5c is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , NO 2 , CN, (CH 2 ) r NR 5f R 5f , (CH 2 ) r OH, (CH 2 ) r OC 1-4 alkyl, (CH 2 ) r SC 1-4 alkyl, (CH 2 ) r C(O)OH, (CH 2 ) r C(O)R 5b , (CH 2 ) r C(O)NR 5f R 5f , (CH 2 ) r NR 5f C(O)R 5b , (CH 2 ) r C(O)OC 1-4 alkyl, (CH 2 ) r OC(O)R 5b , (CH 2 ) r C( ⁇ NR 5f )NR
  • R 5d is selected from methyl, CF 3 , C 2-6 alkyl substituted with 0-2 R 5e , C 3-8 alkenyl substituted with 0-2 R 5e , C 3-8 alkynyl substituted with 0-2 R 5e , and a C 3-10 carbocyclic residue substituted with 0-3 R 5e ;
  • R 5e at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 5f R 5f , and (CH 2 ) r phenyl; R 5f , at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
  • R 5g is independently selected from —C(O)R 5b , —C(O)OR 5d , —C(O)NR 5f R 5f , and (CH 2 ) r phenyl;
  • R at each occurrence, is selected from H, C 1-6 alkyl substituted with R 5e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 5e ;
  • R 6 is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 6a R 6a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 6d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 6d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 6b , (CR′R′) r NR 6a R 6a , (CR′R′) r C(O)NR 6a R 6a , (CR′R′) r NR 6f C(O
  • R 6 on adjacent atoms on R 1 may join to form a cyclic acetal
  • R 6a is selected from H, methyl substituted with 0-1 R 6g , C 2-6 alkyl substituted with 0-2 R 6e , C 3-8 alkenyl substituted with 0-2 R 6e , C 3-8 alkynyl substituted with 0-2 R 6e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-5 R 6e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 6e ;
  • R 6b is selected from H, C 1-6 alkyl substituted with 0-2 R 6e , C 3-8 alkenyl substituted with 0-2 R 6e , C 3-8 alkynyl substituted with 0-2 R 6e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0-3 R 6e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 6e ;
  • R 6d is selected from C 3-8 alkenyl substituted with 0-2 R 6e , C 3-8 alkynyl substituted with 0-2 R 6e , methyl, CF 3 , C 2-6 alkyl substituted with 0-3 R 6e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-3 R 6e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 6e ;
  • R 6e at each occurrence, is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl; R 6f , at each occurrence, is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
  • R 6g is independently selected from —C(O)R 6b , —C(O)OR 6d , —C(O)NR 6f R 6f , and (CH 2 ) r phenyl;
  • R 7 is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CR′R′) r NR 7a R 7a , (CR′R′) r OH, (CR′R′) r O(CR′R′) r R 7d , (CR′R′) r SH, (CR′R′) r C(O)H, (CR′R′) r S(CR′R′) r R 7d , (CR′R′) r C(O)OH, (CR′R′) r C(O)(CR′R′) r R 7b , (CR′R′) r C(O)NR 7a R 7a , (CR′R′) r NR 7f C(O)(CR′R′) r R 7b , (CR′R′) r C
  • R 7 on adjacent atoms on R 2 may join to form a cyclic acetal
  • R 7a is independently selected from H, methyl substituted with 0-1 R 7g , C 2-6 alkyl substituted with 0-2 R 7e , C 3-8 alkenyl substituted with 0-2 R 7e , C 3-8 alkynyl substituted with 0-2 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-5 R 7e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 7e ;
  • R 7b is selected from C 1-6 alkyl substituted with 0-2 R 7e , C 3-8 alkenyl substituted with 0-2 R 7e , C 3-8 alkynyl substituted with 0-2 R 7e , a (CH 2 ) r C 3-6 carbocyclic residue substituted with 0-3 R 7e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 7e ;
  • R 7d is selected from C 3-8 alkenyl substituted with 0-2 R 7e , C 3-8 alkynyl substituted with 0-2 R 7e , methyl, CF 3 , C 2-6 alkyl substituted with 0-3 R 7e , a (CH 2 ) r —C 3-10 carbocyclic residue substituted with 0-3 R 7e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 7e ;
  • R 7e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
  • R 7f is selected from H, C 1-5 alkyl, and C 3-6 cycloalkyl, and phenyl;
  • R 7g is independently selected from —C(O)R 7b , —C(O)OR 7d , —C(O)NR 7f R 7f , and (CH 2 ) r phenyl;
  • R′ at each occurrence, is selected from H, C 1-6 alkyl substituted with R 6e , C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e ;
  • R 8 is selected from H, C 1-4 alkyl, and C 3-4 cycloalkyl
  • R 9 is selected from, H, C 1-4 alkyl, C 3-4 cycloalkyl, and (CH 2 )—R 1 ;
  • R 10 and R 10a are independently selected from H, and C 1-4 alkyl substituted with 0-1 R 10b ,
  • R 10 and R 10a can join to form a C 3-6 cycloalkyl
  • R 10b is independently selected from —OH, —SH, —NR 10c R 10c , —C(O)NR 10c R 10c , and —NHC(O)R 10c ;
  • R 10c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl
  • R 11 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 11d , (CHR) q S(O) p R 11d , (CHR) r C(O)R 11b , (CHR) r NR 11a R 11a , (CHR) r C(O)NR 11a R 11a , (CHR) r C(O)NR 11a OR 11d , (CHR) q NR 11a C(O)R 11b , (CHR) q NR 11a C(O)OR 11d , (CHR) q OC(O)NR 11a R 11a , (CHR) r C(O)OR 11d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0-5 R 11e , and a (CHR) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from
  • R 11b is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 11e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 11e ;
  • R 11d is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0-3 R 11e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 11e ;
  • R 11e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 11f R 11f , and (CH 2 ) r phenyl;
  • R 11f at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
  • R 12 is selected from H, C 1-4 alkyl, (CHR) q OH, (CHR) q SH, (CHR) q OR 12d , (CHR) q S(O) p R 12d , (CHR) r C(O)R 12b , (CHR) r NR 12a R 12a , (CHR) r C(O)NR 12a R 12a , (CHR) r C(O)NR 12a OR 12d , (CHR) q NR 12a C(O)R 12b , (CHR) NR 12a C(O)OR 12d , (CHR) q OC(O)NR 12a R 12a , (CHR) r C(O)OR 12d , a (CHR) r —C 3-6 carbocyclic residue substituted with 0-5 R 12e , and a (CHR) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N,
  • R 12a is independently selected from H, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-5 R 12e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 12e ;
  • R 12b is independently selected from C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, a (CH 2 ) r —C 3-6 carbocyclic residue substituted with 0-2 R 12e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 12e ;
  • R 12d is independently selected from H, methyl, —CF 3 , C 2-4 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, a C 3-6 carbocyclic residue substituted with 0-3 R 12e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 12e ;
  • R 12e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, —O—C 1-6 alkyl, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 12f R 12f , and (CH 2 ) r phenyl;
  • R 12f at each occurrence, is selected from H, C 1-6 alkyl, and C 3-6 cycloalkyl;
  • R 13 at each occurrence, is independently selected from methyl, C 2-4 alkyl substituted with 0-1 R 13b ;
  • R 13b is selected from —OH, —SH, —NR 13c R 13c , —C(O)NR 13c R 13c , and —NHC(O)R 13c ;
  • R 13c is selected from H, C 1-4 alkyl and C 3-6 cycloalkyl
  • n is selected from 1 and 2;
  • n is selected from 0 and 1;
  • p at each occurrence, is independently selected from 0, 1, and 2;
  • q at each occurrence, is independently selected from 1, 2, 3, and 4;
  • r at each occurrence, is independently selected from 0, 1, 2, 3, and 4;
  • s at each occurrence, is independently selected from 0 and 1;
  • t at each occurrence, is independently selected from 2, 3, and 4.
  • R 10 and R 10a are H
  • n 0;
  • n 1;
  • the Present Invention Provides Novel Compounds of Formula (I), Wherein ring B is selected from
  • ring B being optionally substituted with 0-1 R 5 and
  • R 11 and R 12 are H.
  • R 5 is independently selected from H, C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r OH, (CRR) r SH, (CRR) r OR 5d , (CRR) r SR 5d , (CRR) r NR 5a R 5a , (CRR) r C(O)OH, (CRR) r C(O)R 5b , (CRR) r C(O)NR 5a R 5a , (CRR) r NR 5a C(O)R 5b , (CRR) r NR 5a C(O)OR 5d , (CRR) r OC(O)NR 5a R 5a , (CHR) r NR 5a C(O)NR 5a R 5a , CRR(CRR) r NR 5a C(O)H, (CRR) r C(O)OR 5b , (CRR)
  • R 5a is independently selected from H, methyl, C 1-6 alkyl substituted with 0-2 R 5e wherein the alkyl is selected from ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, C 3 alkenyl substituted with 0-1 R 5e , wherein the alkenyl is selected from allyl, C 3 alkynyl substituted with 0-1 R 5e wherein the alkynyl is selected from propynyl, and a (CH 2 ) r —C 3-4 carbocyclic residue substituted with 0-5 R 5e , wherein the carbocyclic residue is selected from cyclopropyl, and cyclobutyl;
  • R 5b is selected from C 1-6 alkyl substituted with 0-2 R 5e , wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, and hexyl, a (CH 2 ) r —C 3-4 carbocyclic residue substituted with 0-2 R 5e , wherein the carbocyclic residue is selected from cyclopropyl, and cyclobutyl; and
  • R 5d is selected from methyl, CF 3 , C 2-6 alkyl substituted with 0-2 R 5e , wherein the alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, and hexyl, C 3-8 alkenyl, C 3-8 alkynyl, and a C 3-10 carbocyclic residue substituted with 0-3 R 5e .
  • R 4 is selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, (CRR) q OH, (CRR) t SH, (CRR) t OR 4d , (CRR) t SR 4d , (CRR) t NR 4a R 4a , (CRR) q C(O)OH, (CRR) r C(O)R 4b , (CRR) r C(O)NR 4a R 4a , (CRR) t NR 4a C(O)R 4b , (CRR) t OC(O)NR 4a R 4a , (CRR) t NR 4a C(O)OR 4d , (CRR) t NR 4a C(O)R 4b , (CRR) r C(O)OR 4b , (CRR) t OC(O)R 4b , (CRR) r S(O) p R 4b
  • R at each occurrence, is independently selected from H, methyl, ethyl, propyl, allyl, propynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e ;
  • R 5 is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CH 2 ) r OH, (CH 2 ) r OR 5d , (CH 2 ) r NR 5a R 5a , (CH 2 ) r C(O)OH, (CH 2 ) r C(O)R 5b , (CH 2 ) r C(O)NR 5a R 5a , (CH 2 ) r NR 5a C(O)R 5b , (CH 2 ) r OC(O)NR 5a R 5a , (CH 2 ) r NR 5a C(O)OR 5d , (CH 2 ) r NR 5a C(O)R 5b , (CH 2 ) r C (O)OR 5b , (CH 2 ) r OC(O)R 5b ,
  • R 5a at each occurrence, is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, cyclopropyl, and cyclobutyl; and r, at each occurrence, is selected from 0, 1, and 2.
  • R 1 is selected from phenyl substituted with 0-2 R 6 , and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 6 wherein the heteroaryl is selected from benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl, quina
  • R 2 is selected from phenyl substituted with 0-2 R 7 , and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 7 wherein the heteroaryl is selected from benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl, quina
  • R 4 is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CRR) q OH, (CRR) s SH, (CRR) s OR 4d , (CRR) s SR 4d , (CRR) s NR 4a R 4a , (CRR) q C(O)OH, (CRR) r C(O)R 4b , (CRR) r C(O)NR 4a R 4a , (CRR) s NR 4a C(O)R 4b , (CRR) s OC(O)NR 4a R 4a , (CRR) s NR 4a C(O)OR 4d , (CRR) s NR 4a C(O)R 4b , (CRR) r C(O)OR 4b , (CRR) s OC(O)R 4b
  • R 4b is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, and cyclopropyl;
  • R 4d is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, and cyclopropyl;
  • R 8 and R 9 are independently selected from methyl, ethyl, propyl, i-propyl, and cyclopropyl.
  • R 6 is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CRR) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CRR) r NR 6a R 6a , (CRR) r OH, (CRR) r O(CRR) r R 6d , (CRR) r SH, (CRR) r C(O)H, (CRR) r S(CRR) r R 6d , (CRR) r C(O)OH, (CRR) r C(O)(CRR) r R 6b , (CRR) r C(O)NR 6a R 6a , (CRR) r NR 6f C(O)(CRR) r R 6b , (CRR) r C(O)O(CRR) r R 6d , (CRR) r NR 6a
  • R 6a is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl and phenyl;
  • R 6b at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
  • R 6d is selected from methyl, CF 3 , ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
  • R 6e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl;
  • R 6f is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
  • R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, (CRR) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CRR) r NR 7a R 7a , (CRR) r OH, (CRR) r O(CH) r R 7d , (CRR) r SH, (CRR) r C(O)H, (CRR) r S(CRR) r R 7d , (CRR) r C(O)OH, (CRR) r C(O)(CRR) r R 7b , (CRR) r C(O)NR 7a R 7a , (CRR) r NR 7f C(O)(CRR) r R 7b , (CRR) r C
  • R 7a is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, prop-2-enyl, 2-methyl-2-propenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH 2 cyclopropyl, and benzyl;
  • R 7b is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, cyclopentyl, CH 2 -cyclopentyl, cyclohexyl, CH 2 -cyclohexyl, CF 3 , pyrrolidinyl, morpholinyl, and azetidinyl;
  • R 7d is selected from methyl, CF 3 , ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and cyclopropyl;
  • R 7e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
  • R 7f is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
  • r is 0 or 1.
  • R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, Cl, Br, I, F, NO 2 , NR 7a R 7a , NHC(O) NHR 7a , NR 7a C(O)R 7b , NR 7a C(O)OR 7d , CF 3 , OCF 3 , C(O)R 7b , NR 7f C(O)NR 7a R 7a , NHS(O) 2 R 7b ,
  • ring B is selected from
  • R 1a and R 1b are selected from H and methyl, or alternatively, R 1a and R 1b are taken together to form ⁇ O;
  • R 1 is selected from a C 6-10 aryl group substituted with 0-3 R 6 wherein the aryl group is selected from phenyl and naphthyl, and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N and O, substituted with 0-3 R 6 wherein the heteroaryl system is selected from furyl, indolyl, and benzotriazolyl;
  • R 2 is phenyl substituted with 0-1 R 7 ;
  • R 4 is selected from H, methyl, ethyl, propyl, i-propyl, butyl, I-butyl, t-butyl, pentyl, hexyl, and (CH 2 ) r C(O)R 4b ;
  • R 6 is selected from methyl, ethyl, propyl, i-propyl, butyl, F, Cl, Br, I, NO 2 , CN, O(CH 2 ) r R 6d , C(O)H, SR 6d , NR 6a R 6a , OC(O)R 6b , S(O) p R 6b , (CHR′) r S(O) 2 NR 6a R 6a , CF 3 ;
  • R 6a is H methyl, or ethyl
  • R 6b is H or methyl
  • R 6d is methyl, phenyl, CF 3 , and (CH 2 )-phenyl;
  • R 9 is selected from H, methyl, and (CH 2 )—R 1 ;
  • r is 0 or 1.
  • the Present Invention Provides Novel Compounds of Formula (I), wherein the Compound is Selected from
  • the present invention is directed to a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for modulation of chemokine or chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for modulation of MCP-1, MCP-2, MCP-3 and MCP-4, and MCP-5 activity that is mediated by the CCR2 receptor comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for modulation of MCP-1 activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for treating or preventing disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), said disorders being selected from osteoarthritis, aneurism, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
  • a compound of Formula (I) said disorders being selected from osteoarthritis, aneurism, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia
  • the present invention is directed to a method for treating or preventing disorders, of Formula (I), wherein said disorders being selected from psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
  • the present invention is directed to a method for treating or preventing disorders, of Formula (I), wherein said disorders being selected from alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
  • disorders being selected from alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
  • the present invention is directed to a method for treating or preventing disorders, of Formula (I), wherein said disorders being selected from asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
  • the present invention is directed to a method for treating or preventing rheumatoid arthritis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for treating or preventing multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for treating or preventing atherosclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • the present invention is directed to a method for modulation of CCR2 activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I).
  • ring B is selected from
  • ring B being optionally substituted with 0-1 R 5 .
  • ring B is selected from
  • Z is —C(O)—.
  • R 4 is selected from H, C 1-6 alkyl, C 3-8 alkenyl, C 3-8 alkynyl, (CRR) q OH, (CHR) s SH, (CRR) t OR 4d , (CHR) t SR 4d , (CHR) t NR 4a R 4a , (CHR) q C(O)H, (CHR) r C(O)R 4b , (CHR) r C(O)NR 4a R 4a , (CHR) t NR 4a C(O)R 4b , (CHR) t OC(O) NR 4a R 4a , (CHR) t NR 4a C(O)OR 4d , (CHR) t NR 4a C(O)R 4b , (CHR) r C(O)OR 4b , (CHR) t OC(O)R 4b , (CHR) r S(O) p
  • R at each occurrence, is independently selected from H, methyl, ethyl, propyl, allyl, propynyl, (CH 2 ) r C 3-6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 6e .
  • R 4 is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CRR) q OH, (CRR) t SH, (CRR) t OR 4d , (CRR) t SR 4d , (CRR) t NR 4a R 4a , (CRR) q C(O)OH, (CRR) r C(O)R 4b , (CRR) r C(O)NR 4a R 4a , (CRR) t NR 4a C(O)R 4b , (CRR) t OC(O)NR 4a R 4a , (CRR) t NR 4a C(O)OR 4d , (CRR) t NR 4a C(O)R 4b , (CRR) r C(O)OR 4b , (CRR) t OC(O)R
  • R 4b is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, and cyclopropyl;
  • R 4d is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, and cyclopropyl.
  • R 4 is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CH 2 ) r C(O)R 4b .
  • R 5 is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, allyl, propynyl, (CH 2 ) r OH, (CH 2 ) r OR 5d , (CH 2 ) r NR 5a R 5a , (CH 2 ) r C(O)OH, (CH 2 ) r C(O)R 5b , (CH 2 ) r C(O) NR 5a R 5a , (CH 2 ) r NR 5a C(O)R 5b , (CH 2 ) r OC(O)NR 5a R 5a , (CH 2 ) r NR 5a C(O)OR 5d , (CH 2 ) r NR 5a C(O)R 5b , (CH 2 ) r C(O)OR 5b , (CH 2 ) r OC(O)
  • R 5a is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, pentyl, hexyl, cyclopropyl, and cyclobutyl.
  • R 5 at each occurrence, is independently selected from H, (CH 2 ) r NR 5a R 5a , (CH 2 ) r NR 5a C(O)R 5b , and (CH 2 ) r NR 5a C(O)OR 5 d.
  • R 1 is selected from phenyl substituted with 0-2 R 6 , naphthyl substituted with 0-2 R 6 , and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 6 wherein the heteroaryl is selected from indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl
  • R 1 is selected from a C 6-10 aryl group substituted with 0-3 R 6 wherein the aryl group is selected from phenyl and naphthyl, and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N and O, substituted with 0-3 R 6 wherein the heteroaryl system is selected from furyl, indolyl, and benzotriazolyl.
  • R 2 is selected from phenyl substituted with 0-2 R 7 , and a 5-10 membered heteroaryl system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 7 wherein the heteroaryl is selected from benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl,
  • R 2 is selected from phenyl substituted with 0-2 R 7 .
  • R 6 is selected from C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CH 2 ) r NR 6a R 6a , (CH 2 ) r OH, (CH 2 ) r O(CH 2 ) r R 6d , (CH 2 ) r SH, (CH 2 ) r C(O)H, (CH 2 ) r S(CH 2 ) r R 6d , (CH 2 ) r C(O)OH, (CH 2 ) r C(O)(CH 2 ) r R 6b , (CH 2 ) r C(O)NR 6a R 6a , (CH 2 ) r NR 6 C(O)(CH 2 ) r R 6b , (CH 2 ) r C(O)O(CH
  • R 6a is independently selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl and phenyl;
  • R 6b at each occurrence, is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
  • R 6d is selected from methyl, CF 3 , ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl;
  • R 6e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 6f R 6f , and (CH 2 ) r phenyl; and
  • R 6f is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl.
  • R 6 is selected from methyl, ethyl, propyl, i-propyl, butyl, F, Cl, Br, I, NO 2 , CN, O(CH 2 ) r R 6d , C(O)H, SR 6d , NR 6a R 6a , OC(O)R 6b , S(O) p R 6b , (CHR′) r S(O) 2 NR 6a R 6a , CF 3 ;
  • R 6a is H, methyl, or ethyl
  • R 6b is H or methyl
  • R 6d is methyl, phenyl, CF 3 , and (CH 2 )-phenyl.
  • R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, hexyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, Br, I, F, NO 2 , CN, (CH 2 ) r NR 7a R 7a , (CH 2 ) r OH, (CH 2 ) r O(CH) r R 7d , (CH 2 ) r SH, (CH 2 ) r C(O)H, (CH 2 ) r S(CH 2 ) r R 7d , (CH 2 ) r C(O)OH, (CH 2 ) r C(O)(CH 2 ) r R 7b , (CH 2 ) r C(O)NR 7a R 7a , (CH 2 ) r NR 7f C(O)(CH
  • R 7a is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and cyclopropyl;
  • R 7b is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and cyclopropyl;
  • R 7d is selected from methyl, CF 3 , ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, and cyclopropyl;
  • R 7e is selected from C 1-6 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, (CH 2 ) r C 3-6 cycloalkyl, Cl, F, Br, I, CN, NO 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1-5 alkyl, OH, SH, (CH 2 ) r SC 1-5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl; and
  • R 7f is selected from H, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and phenyl.
  • R 7 is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, pentyl, hexyl, Cl, Br, I, F, NO 2 , NR 7a R 7a , NHC(O)NHR 7a , NR 7a C(O)R 7b , NR 7a C(O)OR 7d , CF 3 , OCF 3 , C(O)R 7b , NR 7f C(O)NHR 7a , and NHS(O) 2 R 7b .
  • R 8 is H.
  • R 9 is H, methyl, or CH 2 —R 1 .
  • R 11 and R 12 are H.
  • the compounds herein described may have asymmetric centers.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • a substitent is keto (i.e., ⁇ O)
  • 2 hydrogens on the atom are replaced.
  • any variable e.g., R a
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • R a e.g., R a
  • said group may optionally be substituted with up to two R a groups and R a at each occurrence is selected independently from the definition of R a .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • C 1-8 alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl.
  • C 1-8 alkyl is intended to include C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , and C 8 alkyl groups.
  • Alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
  • Alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, and the like.
  • C 3-6 cycloalkyl is intended to include saturated ring groups having the specified number of carbon atoms in the ring, including mono-, bi-, or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl in the case of C 7 cycloalkyl.
  • C 3-6 cycloalkyl is intended to include C 3 , C 4 , C 5 , and C 6 cycloalkyl groups
  • 5-6-membered cyclic ketal is intended to mean 2,2-disubstituted 1,3-dioxolane or 2,2-disubstituted 1,3-dioxane and their derivatives.
  • “carbocycle” or “carbocyclic residue” is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl,; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
  • heterocycle or “heterocyclic system” is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another.
  • aromatic heterocyclic system, or “heteroaryl” is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, O and S and is aromatic in nature.
  • heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 1H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
  • the heterocycles include, but are not limited to, pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiaphenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoidolyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
  • heteroaryls are 1H-indazole, 2H,6H-1,5,2-dithiazinyl, indolyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetra
  • heteroaryls are indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.
  • phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington's Pharmaceutical Sciences , 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc . . . ) the compounds of the present invention may be delivered in prodrug form.
  • the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same.
  • “Prodrugs” are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the present invention is intended to embody stable compounds.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention alone or in combination with other active ingredients effective to inhibit MCP-1 or effective to treat or prevent inflammatory disorders.
  • the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.
  • novel compounds of this invention may be prepared using the reactions and techniques described in this section.
  • the reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.
  • a series of compounds of formulas 6 and 7 are available via the methods shown in Scheme 1.
  • a cyclic diamine 1 can be monoprotected to provide 2. This material can be coupled to the acid 3 to yield the amide 4. Once the protecting group is removed, a reductive amination can be performed to afford target 6. This can be alkylated again to give target 7.
  • a series of compounds of formulas 10 and 11 are available as shown in Scheme 2.
  • the protecting group on intermediate 4 can be removed, and a reductive amination can be performed to yield 8.
  • This material can be coupled to acid 9 to give target 10.
  • a second target can be synthesized by protecting group removal from intermediate 4 and direct coupling of 9 to give the target 11.
  • a series of compounds of formulas 20 and 21 are synthesized as shown in Scheme 3.
  • a cyclic 1,2-diamine like 12 (for example, the commercially available 1,2-diaminocyclohexane) can be mono-protected as a Boc carbamate via BOC-ON (Brechbiel et al., Bioorg. Med. Chem . 1997, 5, 1925).
  • the amine 13 can be directly coupled with 14 to yield the amide 15.
  • 13 In a second pathway, or a stepwise version, 13 can be coupled to 16 as the first step.
  • the resulting amide 17 can be deprotected (N-Cbz), and then coupled to 9a to form the same 15.
  • the N-Boc of 15 can be removed to give the key intermediate amine 19.
  • One target can be synthesized via a reductive amination with 5 to yield 20.
  • the second target can be synthesized by performing another reductive amination to give 21.
  • a series of compounds of formulas 23 and 24 can be synthesized as shown in Scheme 4.
  • the key intermediate 19 can be alkyated via reductive amination to give 22.
  • the first target can be synthesized by coupling 22 with 9 to give 23.
  • the second target can be synthesized by direct coupling of 19 with 9 to afford 24.
  • a series of compounds of formulas 32 and 34 are prepared via the methods shown in Scheme 5.
  • An amine 25 for example, the commercially available 2-benzyloxycyclopentylamine) can be protected as the carbamate 26 via Boc 2 O. Removal of the benzyl group affords the alcohol 27, which can be converted to the mesylate 28. The mesylate can be displaced with NaN 3 to provide the azide 29. This can be reduced to the key intermediate 30. This amine can be coupled with 9 to afford the amide 31.
  • the first target can be synthesized by deprotection with TFA followed by coupling with 3 to give 32.
  • Another target can be synthesized from 30 by first performing a reductive amination to give 33. The amine 33 can be coupled to 9, deprotected with TFA, and coupled with 3 to afford the target 34.
  • a series of compounds of formulas 39 and 40 are synthesized as shown in Scheme 6.
  • the key intermediate 30 can be protected as the Cbz carbamate 35 via Cbz 2 O.
  • the Boc group can be removed, and the acid 3 can be coupled to provide amide 37.
  • the amide 37 can be deprotected to the amine 38, and a reductive amination can be performed to give the first target 39.
  • the second target can be synthesized via another reductive amination on 39 to afford 40.
  • intermediate 30 can be converted into several target molecules.
  • 30 can be synthesized several different ways.
  • a cyclic olefin 41 [many are available for this: 1-carbobenzyloxy-1,2,3,6-tetrahydropyridine (D'Andrea et al., J. Org. Chem . 1991, 56, 3133), 4-aminocyclohexene derivatives (Bisagni et al., J. Heterocycl. Chem . 1990, 27, 1801 or Pfister et al. Synthesis 1983, 38-40), or 3-pyrroline derivatives (Lai et al., J. Med. Chem .
  • a series of compounds of formula 58 are synthesized as shown in Scheme 8.
  • the cyclic, unsaturated acid 48 can be converted into the 2-aminocyclocarboxylate 51 via two routes.
  • esterification followed by a Michael reaction gives 50.
  • Simple hydrogenation gives the 2-aminocyclocarboxylate 51.
  • the Michael reaction (Schneider et al., Chem Ber . 1959, 92, 1594) can be performed with ammonia to give 51 after esterification. Going forward, a Cbz group (or another appropriate protecting group) can be installed under standard conditions to afford 52.
  • a series of compounds of formula 64 are synthesized as shown in Scheme 9.
  • intermediate 52 or another appropriate protecting group for Cbz
  • Enolization of the ester with LDA (or another appropriate base) followed by alkylation gives the substituted 59.
  • the ester is then removed to afford the free acid 60.
  • a Curtius (Yamada et al., Tetrahedron 1974, 30, 2151) or Hofmann reaction (Zhang et al., J. Org. Chem . 1997, 62, 6918) can then be performed to give the diamino derivative 61 (as in 35, Scheme 6).
  • the Cbz can be removed via hydrogenation to give the free amine 62.
  • this material can be coupled to the right-side piece 3 to give the amide 63. This can then be elaborated as shown in Scheme 3, 4, 5, and 6 to give the desired target 64.
  • a series of compounds of formula 74 are synthesized as shown in Scheme 10.
  • a cyclic ester acid 65 can be alkylated with LDA (or another appropriate base) and the electrophile R 11 -LG to give 66.
  • This material can be esterified via the isourea (Mathias Synthesis 1979, 561) to afford the diester 67.
  • Hydrolysis leads to the acid 68 which can undergo a Curtius or a Hofmann to give 69 (or another appropriate protecting group for Cbz).
  • the ester can be alkylated with the electrophile R 12 -LG to provide 70.
  • the tert-butyl ester can be removed to the acid 71, and a Curtius or Hofmann reaction provides the amine 72 (much like 35, Scheme 6). As before, 72 can be coupled to the right-side piece 3 to give the amide 73. This can then be elaborated as shown in Scheme 3, 4, 5, and 6 to give the desired target 74.
  • racemic material can be achieved by HPLC using a chiral column or by a resolution using a resolving agent such as camphonic chloride as in Steven D. Young, et al, Antimicrobial Agents and Chemotheraphy , 1995, 2602-2605.
  • EtOAc was added along with 1 N HCl solution.
  • the EtOAc layer was washed with 1 N HCl, NaHCO 3 solution, and brine.
  • the EtOAc was dried (MgSO 4 ), filtered, and concentrated (14.6 g).
  • the resulting residue was dissolved in CH 2 Cl 2 (20 mL) prior to the addition of TFA (20 mL). After 15 min, the solution was concentrated to a foam.
  • This material was dissolved in DMF (70 mL). After cooling to 0° C., diisopropylethylamine (25 mL) and 4-aminosulfonylbenzoic acid (8.7 g) were added. BOP Reagent (19.2 g) was added, and the mixture was stirred overnight.
  • Example 104 step 104c, was altered as follows. [(Cis)-2-[[[[(2-(allylamino)-5-trifluoromethyl)benzoyl]amino]acetyl]amino]cyclohexyl]carbamic acid tert-butyl ester from 104(b) (360 mg) was dissolved in 4M HCl/dioxane(10 mL). After stirring for 2 h, the solution was concentrated. A portion (300 mg) of the resulting residue was dissolved in MeOH (5 mL) and 10% Pd/C was added. A hydrogen balloon was added and the solution was stirred for 2 h. The palladium was filtered and the solution was concentrated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
US10/027,644 2000-12-20 2001-12-20 Cyclic derivatives as modulators of chemokine receptor activity Expired - Lifetime US6706712B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/027,644 US6706712B2 (en) 2000-12-20 2001-12-20 Cyclic derivatives as modulators of chemokine receptor activity
US10/706,448 US7045521B2 (en) 2000-12-20 2003-11-12 Cyclic derivatives as modulators of chemokine receptor activity
US11/315,385 US7572813B2 (en) 2000-12-20 2005-12-22 Cyclic derivatives as modulators of chemokine receptor activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25690400P 2000-12-20 2000-12-20
US10/027,644 US6706712B2 (en) 2000-12-20 2001-12-20 Cyclic derivatives as modulators of chemokine receptor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/706,448 Division US7045521B2 (en) 2000-12-20 2003-11-12 Cyclic derivatives as modulators of chemokine receptor activity

Publications (2)

Publication Number Publication Date
US20030004151A1 US20030004151A1 (en) 2003-01-02
US6706712B2 true US6706712B2 (en) 2004-03-16

Family

ID=22974088

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/027,644 Expired - Lifetime US6706712B2 (en) 2000-12-20 2001-12-20 Cyclic derivatives as modulators of chemokine receptor activity
US10/706,448 Expired - Lifetime US7045521B2 (en) 2000-12-20 2003-11-12 Cyclic derivatives as modulators of chemokine receptor activity
US11/315,385 Expired - Lifetime US7572813B2 (en) 2000-12-20 2005-12-22 Cyclic derivatives as modulators of chemokine receptor activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/706,448 Expired - Lifetime US7045521B2 (en) 2000-12-20 2003-11-12 Cyclic derivatives as modulators of chemokine receptor activity
US11/315,385 Expired - Lifetime US7572813B2 (en) 2000-12-20 2005-12-22 Cyclic derivatives as modulators of chemokine receptor activity

Country Status (7)

Country Link
US (3) US6706712B2 (fr)
EP (1) EP1343751A2 (fr)
JP (1) JP2004523534A (fr)
AR (1) AR035773A1 (fr)
CA (1) CA2432369A1 (fr)
HU (1) HUP0303652A2 (fr)
WO (1) WO2002060859A2 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030060459A1 (en) * 2000-12-20 2003-03-27 Percy Carter Diamines as modulators of chemokine receptor activity
US20030119885A1 (en) * 2001-09-13 2003-06-26 Du Bois Daisy Joe CCR-3 receptor antagonists
US20030216434A1 (en) * 2002-03-08 2003-11-20 Cherney Robert J. Cyclic derivatives as modulators of chemokine receptor activity
US20040110736A1 (en) * 2000-12-20 2004-06-10 Robert Cherney Cyclic derivatives as modulators of chemokine receptor activity
US20040186143A1 (en) * 2003-02-12 2004-09-23 Carter Percy H. Lactams as modulators of chemokine receptor activity
US20040235836A1 (en) * 2003-05-01 2004-11-25 Cherney Robert J. Cyclic derivatives as modulators of chemokine receptor activity
US20040235835A1 (en) * 2003-05-01 2004-11-25 Percy Carter Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) * 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US20050054627A1 (en) * 2003-08-21 2005-03-10 Carter Percy H. Cyclic derivatives as modulators of chemokine receptor activity
US20050054626A1 (en) * 2003-08-21 2005-03-10 Carter Percy H. Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US20050065147A1 (en) * 2003-08-21 2005-03-24 Carter Percy H. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
WO2004071460A3 (fr) * 2003-02-12 2005-10-20 Bristol Myers Squibb Co Derives cycliques utilises comme modulateurs de l'activite des recepteurs de chimiokines
US20070197516A1 (en) * 2003-08-21 2007-08-23 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US20080027084A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Modulators of chemokine receptor activity crystalline forms and process
US20080027083A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Modulators of chemokine receptor activity crystalline forms and process
US20080027080A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US20110086857A1 (en) * 2009-10-13 2011-04-14 Bristol-Myers Squibb Company N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CN102933575A (zh) * 2010-06-09 2013-02-13 詹森药业有限公司 Ccr2的环己基-氮杂环丁烷基拮抗剂

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
US7067538B2 (en) 2002-08-09 2006-06-27 Warner-Lambert Company, Llc MCP-1 receptor antagonists and methods of use thereof
AU2003286701B2 (en) * 2002-10-30 2008-12-18 Merck Sharp & Dohme Corp. Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity
US7351720B2 (en) 2003-06-12 2008-04-01 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1676837A4 (fr) * 2003-10-08 2008-09-10 Teijin Pharma Ltd Methode de production d'un derive d'aminopyrrolidine et d'un compose intermediaire
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (fr) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
WO2009061830A1 (fr) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Méthodes et compositions pour traiter des troubles associés à l'angiogenèse à l'aide d'un inhibiteur de la protéine-1 d'adhésion vasculaire (vap-1)
UY32312A (es) * 2008-12-10 2010-06-30 Janssen Pharmaceutica Nv 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
WO2010121011A1 (fr) * 2009-04-16 2010-10-21 Janssen Pharmaceutica Nv Dérivés de 4-azétidinyl-1-hétéroaryl-cyclohexane en tant qu'antagonistes de ccr2
NZ595432A (en) * 2009-04-17 2013-12-20 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
WO2010121036A1 (fr) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv Antagonistes de ccr2 à base de 4-azétidinyl-1-hétéroatome-cyclohexane
EP2582692B1 (fr) 2010-06-17 2015-07-22 Janssen Pharmaceutica NV Cyclohexyl-azetidines commme inhibiteurs de la ccr2
WO2014151953A1 (fr) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Composés et procédés pour l'induction de la chondrogenèse
US10717708B2 (en) * 2015-12-10 2020-07-21 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264795A2 (fr) 1986-10-22 1988-04-27 MERCK PATENT GmbH Derivés amino-acides
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JPH0377869A (ja) 1989-08-17 1991-04-03 Yoshitomi Pharmaceut Ind Ltd アルキレンビスアミド化合物
WO1993015047A1 (fr) 1992-01-28 1993-08-05 British Bio-Technology Limited Derives d'aminoacides utilises comme antagonistes de facteur d'activation plaquettaire (paf)
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
WO1994003479A1 (fr) 1992-07-30 1994-02-17 Cor Therapeutics, Inc. Antagonistes de recepteurs de la thrombine
WO1994020062A2 (fr) 1993-03-03 1994-09-15 Eli Lilly And Company Balanoides utilisables comme inhibiteurs de la proteine kinase c
WO1996022966A1 (fr) 1995-01-23 1996-08-01 Biogen, Inc. Inhibiteurs de l'adherence cellulaire
EP0731107A1 (fr) 1995-02-13 1996-09-11 Takeda Chemical Industries, Ltd. Préparation de dérivés d'aldéhydes
WO1997000894A1 (fr) 1995-06-22 1997-01-09 Novo Nordisk A/S Composes presentant des proprietes de liberation de l'hormone de croissance
WO1997044329A1 (fr) 1996-05-20 1997-11-27 Teijin Limited Derives de diamine cyclique de diarylaklyle utilises en tant qu'antagonistes des recepteurs de chimiokines
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
WO1998006703A1 (fr) 1996-08-14 1998-02-19 Warner-Lambert Company Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1
US5770620A (en) 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
WO1999007351A2 (fr) 1997-08-07 1999-02-18 Zeneca Limited Composes chimiques
WO1999007678A1 (fr) 1997-08-07 1999-02-18 Zeneca Limited Derives d'indole utiles en tant qu'antagonistes du recepteur mcp-1
WO1999017790A1 (fr) 1997-10-07 1999-04-15 Cephalon Inc. Inhibiteurs de cysteine et de serine proteases, a base d'alpha-cetoamides contenant des peptides
WO1999025686A1 (fr) 1997-11-18 1999-05-27 Teijin Limited Derives d'amine cyclique et leur utilisation en tant que medicaments
WO1999040914A1 (fr) 1998-02-17 1999-08-19 Astrazeneca Uk Limited Derives bicycliques du pyrrole, inhibiteurs de la mcp-1
WO1999040913A1 (fr) 1998-02-17 1999-08-19 Astrazeneca Uk Limited Composes chimiques
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5981491A (en) 1995-05-10 1999-11-09 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
US6011052A (en) 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
US6028087A (en) 1998-01-21 2000-02-22 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
US6030946A (en) 1995-06-07 2000-02-29 Axys Pharmaceuticals, Inc. Reversible cysteine protease inhibitors
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6084065A (en) 1993-10-05 2000-07-04 Isagro Spa Oligopeptides with fungicidal activity
WO2000042071A2 (fr) 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Composes et procedes destines a inhiber ou renforcer une reaction inflammatoire
US6100423A (en) 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
WO2000046196A1 (fr) 1999-02-05 2000-08-10 Astrazeneca Ab Derives d'indole et leur utilisation comme antagonistes vis-a-vis de la proteine 1 ayant un chimiotactisme positif sur les monocytes (mcp-1)
WO2000069815A1 (fr) 1999-05-13 2000-11-23 Teijin Limited Derives d'amines cycliques ureido-substituees et leur utilisation en tant que medicament
WO2000069820A1 (fr) 1999-05-14 2000-11-23 Combichem, Inc. Derives d'amine cycliques et leurs utilisations
US6162790A (en) 1995-12-20 2000-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
WO2000076512A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyliques de l'activite du recepteur de la chimiokine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432908A1 (fr) 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines servant de modulateurs de l'activite recepteur des chimiokines
EP1343751A2 (fr) 2000-12-20 2003-09-17 Bristol-Myers Squibb Company Derives cycliques en tant que modulateurs de l'activite des recepteurs de chimiokines
WO2003075853A2 (fr) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine
US7338975B2 (en) 2003-02-12 2008-03-04 Bristol-Myers Squibb Co. Lactams as modulators of chemokine receptor activity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264795A2 (fr) 1986-10-22 1988-04-27 MERCK PATENT GmbH Derivés amino-acides
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
EP0560407A1 (fr) 1986-12-10 1993-09-15 Schering Corporation Composés pharmaceutiquement actifs
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
JPH0377869A (ja) 1989-08-17 1991-04-03 Yoshitomi Pharmaceut Ind Ltd アルキレンビスアミド化合物
WO1993015047A1 (fr) 1992-01-28 1993-08-05 British Bio-Technology Limited Derives d'aminoacides utilises comme antagonistes de facteur d'activation plaquettaire (paf)
WO1994003479A1 (fr) 1992-07-30 1994-02-17 Cor Therapeutics, Inc. Antagonistes de recepteurs de la thrombine
WO1994020062A2 (fr) 1993-03-03 1994-09-15 Eli Lilly And Company Balanoides utilisables comme inhibiteurs de la proteine kinase c
US6084065A (en) 1993-10-05 2000-07-04 Isagro Spa Oligopeptides with fungicidal activity
WO1996022966A1 (fr) 1995-01-23 1996-08-01 Biogen, Inc. Inhibiteurs de l'adherence cellulaire
EP0731107A1 (fr) 1995-02-13 1996-09-11 Takeda Chemical Industries, Ltd. Préparation de dérivés d'aldéhydes
US5981491A (en) 1995-05-10 1999-11-09 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
US6030946A (en) 1995-06-07 2000-02-29 Axys Pharmaceuticals, Inc. Reversible cysteine protease inhibitors
US5770620A (en) 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
WO1997000894A1 (fr) 1995-06-22 1997-01-09 Novo Nordisk A/S Composes presentant des proprietes de liberation de l'hormone de croissance
US6100423A (en) 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
US6162790A (en) 1995-12-20 2000-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6011052A (en) 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
WO1997044329A1 (fr) 1996-05-20 1997-11-27 Teijin Limited Derives de diamine cyclique de diarylaklyle utilises en tant qu'antagonistes des recepteurs de chimiokines
WO1998006703A1 (fr) 1996-08-14 1998-02-19 Warner-Lambert Company Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1
WO1999007678A1 (fr) 1997-08-07 1999-02-18 Zeneca Limited Derives d'indole utiles en tant qu'antagonistes du recepteur mcp-1
WO1999007351A2 (fr) 1997-08-07 1999-02-18 Zeneca Limited Composes chimiques
WO1999017790A1 (fr) 1997-10-07 1999-04-15 Cephalon Inc. Inhibiteurs de cysteine et de serine proteases, a base d'alpha-cetoamides contenant des peptides
WO1999025686A1 (fr) 1997-11-18 1999-05-27 Teijin Limited Derives d'amine cyclique et leur utilisation en tant que medicaments
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6028087A (en) 1998-01-21 2000-02-22 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
WO1999040913A1 (fr) 1998-02-17 1999-08-19 Astrazeneca Uk Limited Composes chimiques
WO1999040914A1 (fr) 1998-02-17 1999-08-19 Astrazeneca Uk Limited Derives bicycliques du pyrrole, inhibiteurs de la mcp-1
WO2000042071A2 (fr) 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Composes et procedes destines a inhiber ou renforcer une reaction inflammatoire
WO2000046196A1 (fr) 1999-02-05 2000-08-10 Astrazeneca Ab Derives d'indole et leur utilisation comme antagonistes vis-a-vis de la proteine 1 ayant un chimiotactisme positif sur les monocytes (mcp-1)
WO2000069815A1 (fr) 1999-05-13 2000-11-23 Teijin Limited Derives d'amines cycliques ureido-substituees et leur utilisation en tant que medicament
WO2000069820A1 (fr) 1999-05-14 2000-11-23 Combichem, Inc. Derives d'amine cycliques et leurs utilisations
WO2000076512A1 (fr) 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs cyclopentyliques de l'activite du recepteur de la chimiokine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Baba et al., A Small-Molecule, Nonpeptide CCR5 Antagonist With Hihgly Potent and Selective Anti-HIV-1 Activity, Proc. Natl. Acad. Sci., May 1999, vol. 96, pp. 5698-5703.
Forbes, et al., CCR2B Receptor Antagonists: Conversion of a Weak HTS it to a Potent Lead Compound, Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, pp. 1803-1806.
Mirzadegan, et al. Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists, The Journal of Biological Chemistry, 2000, vol. 275 No. 33, pp. 25562-25571.

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572813B2 (en) 2000-12-20 2009-08-11 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20040110736A1 (en) * 2000-12-20 2004-06-10 Robert Cherney Cyclic derivatives as modulators of chemokine receptor activity
US6974836B2 (en) 2000-12-20 2005-12-13 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
US20050282882A1 (en) * 2000-12-20 2005-12-22 Percy Carter Diamines as modulators of chemokine receptor activity
US7045521B2 (en) 2000-12-20 2006-05-16 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
US20030060459A1 (en) * 2000-12-20 2003-03-27 Percy Carter Diamines as modulators of chemokine receptor activity
US7449493B2 (en) 2000-12-20 2008-11-11 Bristol-Myers Squibb Pharmaceutical Company Diamines as modulators of chemokine receptor activity
US20030119885A1 (en) * 2001-09-13 2003-06-26 Du Bois Daisy Joe CCR-3 receptor antagonists
US7049317B2 (en) * 2001-09-13 2006-05-23 Syntex (U.S.A.) Llc CCR-3 receptor antagonists
US7776884B2 (en) 2002-03-08 2010-08-17 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptors activity
US20060135503A1 (en) * 2002-03-08 2006-06-22 Cherney Robert J Cyclic derivatives as modulators of chemokine receptors activity
US7087604B2 (en) * 2002-03-08 2006-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20030216434A1 (en) * 2002-03-08 2003-11-20 Cherney Robert J. Cyclic derivatives as modulators of chemokine receptor activity
WO2004071460A3 (fr) * 2003-02-12 2005-10-20 Bristol Myers Squibb Co Derives cycliques utilises comme modulateurs de l'activite des recepteurs de chimiokines
US20040186143A1 (en) * 2003-02-12 2004-09-23 Carter Percy H. Lactams as modulators of chemokine receptor activity
US20080114052A1 (en) * 2003-02-12 2008-05-15 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7338975B2 (en) 2003-02-12 2008-03-04 Bristol-Myers Squibb Co. Lactams as modulators of chemokine receptor activity
US7338947B2 (en) 2003-02-12 2008-03-04 Bristol-Myers Squibb Co. Cyclic derivatives as modulators of chemokine receptor activity
US7183270B2 (en) 2003-02-12 2007-02-27 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20070032541A1 (en) * 2003-02-12 2007-02-08 Cherney Robert J Cyclic derivatives as modulators of chemokine receptor activity
US20040235835A1 (en) * 2003-05-01 2004-11-25 Percy Carter Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US20080108678A1 (en) * 2003-05-01 2008-05-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US20040235836A1 (en) * 2003-05-01 2004-11-25 Cherney Robert J. Cyclic derivatives as modulators of chemokine receptor activity
US20070213379A1 (en) * 2003-05-01 2007-09-13 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7696205B2 (en) 2003-05-01 2010-04-13 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7468440B2 (en) 2003-05-01 2008-12-23 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US20050054626A1 (en) * 2003-08-21 2005-03-10 Carter Percy H. Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US20080113976A1 (en) * 2003-08-21 2008-05-15 Bristol-Myers Squibb Company N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US20050065147A1 (en) * 2003-08-21 2005-03-24 Carter Percy H. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US20070032526A1 (en) * 2003-08-21 2007-02-08 Carter Peroy H Cyclic derivatives as modulators of chemokine receptor activity
US7829571B2 (en) 2003-08-21 2010-11-09 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20050054627A1 (en) * 2003-08-21 2005-03-10 Carter Percy H. Cyclic derivatives as modulators of chemokine receptor activity
US7863317B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) * 2003-08-21 2005-02-24 Carter Percy H. Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7863333B2 (en) 2003-08-21 2011-01-04 Bristol-Myers Squibb Company N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US7482335B2 (en) 2003-08-21 2009-01-27 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US20070197516A1 (en) * 2003-08-21 2007-08-23 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US20080027083A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Modulators of chemokine receptor activity crystalline forms and process
US20080027084A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Modulators of chemokine receptor activity crystalline forms and process
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US20100113489A1 (en) * 2006-07-28 2010-05-06 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US8049019B2 (en) 2006-07-28 2011-11-01 Bristol-Myers Squibb Company Substituted pyrrolidine-2-one compounds
US20080027080A1 (en) * 2006-07-28 2008-01-31 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US20110086857A1 (en) * 2009-10-13 2011-04-14 Bristol-Myers Squibb Company N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US8618101B2 (en) 2009-10-13 2013-12-31 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US8906920B2 (en) 2009-10-13 2014-12-09 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CN102933575A (zh) * 2010-06-09 2013-02-13 詹森药业有限公司 Ccr2的环己基-氮杂环丁烷基拮抗剂
CN102933575B (zh) * 2010-06-09 2015-02-04 詹森药业有限公司 Ccr2的环己基-氮杂环丁烷基拮抗剂

Also Published As

Publication number Publication date
US20060135502A1 (en) 2006-06-22
US20030004151A1 (en) 2003-01-02
US7572813B2 (en) 2009-08-11
WO2002060859A2 (fr) 2002-08-08
CA2432369A1 (fr) 2002-08-08
AR035773A1 (es) 2004-07-14
WO2002060859A3 (fr) 2003-03-27
US7045521B2 (en) 2006-05-16
US20040110736A1 (en) 2004-06-10
JP2004523534A (ja) 2004-08-05
HUP0303652A2 (hu) 2004-03-01
EP1343751A2 (fr) 2003-09-17

Similar Documents

Publication Publication Date Title
US6706712B2 (en) Cyclic derivatives as modulators of chemokine receptor activity
US7776884B2 (en) Cyclic derivatives as modulators of chemokine receptors activity
US7468440B2 (en) Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7449493B2 (en) Diamines as modulators of chemokine receptor activity
US7696205B2 (en) Cyclic derivatives as modulators of chemokine receptor activity
US7863333B2 (en) N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US7338975B2 (en) Lactams as modulators of chemokine receptor activity
US7381738B2 (en) Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US20050043392A1 (en) Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7863317B2 (en) Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
AU2002248244A1 (en) Cyclic derivatives as modulators of chemokine receptor activity

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (FORME

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHERNEY, ROBERT;REEL/FRAME:012728/0045

Effective date: 20020227

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: BRISTOL-MYERS SQUIBB PHARMA COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHERNEY, ROBERT;REEL/FRAME:016927/0588

Effective date: 20051221

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12